Reduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatients.

Vafa Bayat Russell Ryono Steven Phelps Eugene Geis Farshid Sedghi Payam Etminani Mark Holodniy

Published in: Open forum infectious diseases (2021)

If confirmed by prospective clinical trials, our results suggest that ondansetron, a safe, widely available drug, could be used to decrease morbidity and mortality in at-risk populations.

Keyphrases

sars cov
clinical trial
chemotherapy induced
respiratory syndrome coronavirus
cardiovascular events
risk factors
phase ii
genetic diversity
open label
drug induced
double blind
phase iii